Abstract:
A unit dosage form, such as a capsule or the like, for delivering a skeletal muscle relaxant, such as cyclobenzaprine hydrochloride, into the body in an extended or sustained release fashion comprising one or more populations of drug-containing particles (beads, pellets, granules, etc.) is disclosed along with a method of preparation therefor. The dosage form comprises active core particles which are individually surrounded by a water insoluble polymer coating which lacks plasticizer.
Abstract:
The present invention is based on the seminal discovery of a set of biomarker assays to predict the risk of esophageal cancer or ad vanced precancerous esophageal lesions in patients with Barrett's esophagus (BE). The present invention includes, but is not restricted to biomarkers based on gene hypermethylation (CH3), as well as biomarkers based on loss of heterozygosity (LOH), both occurring in Barrett's esophagus tissue biopsy samples. Results of the assay provide patients and their caregivers with an assessment of the likelihood of future neoplastic (irankiy cancerous or advanced precancerous) progression.
Abstract:
This invention involves the use of a more effective adsorbent to dehydrate ethanol. The most common use for the ethanol is an additive to gasoline. The preferred adsorbent is a type 3A adsorbent that has been ion exchanged with potassium at a level of 0.6. Surprisingly, this adsorbent has a significantly improved resistance to damage by water upset events.
Abstract:
A charge pump (200) can be used with a bus-powered device connected to a bus. The charge pump (200) comprises a power connection (210) from the bus carrying a DC power signal constrained to not exceed a given current limit and a given voltage limit, a DC-to-DC step-down voltage converter (300), a capacitor (C1), and a DC-to-DC step-up voltage converter (400). The step-down converter (300) has an input connected to the power connection (210) and produces an intermediate signal having a voltage the same or less than the voltage of the power signal. The capacitor (C1) is connected to the output of the step-down converter (300). The step-up converter (400) has an input connected to the output of the step-down converter (300) and to the capacitor (C1), and produces a final output signal having a voltage greater than the given voltage limit. The output of the step-up converter (400) is connected to and provides DC power to the device.
Abstract:
A cleaning composition is provided comprising a solvent system and at least one inorganic alkaline salt, wherein the solvent system includes at least one polyhydric alcohol. The inventive composition may also include a thickener, a corrosion-inhibition system, surfactant. The invention also provides a method of cleaning soil from a cooking related surface comprising, applying a cleaning composition to the surface, allowing the cleaning composition to remain on the surface for a period of time and removing the composition from the surface along with the soil. After application of the composition, the surface can be heated prior to removal of the composition and soil from the surface.
Abstract:
In clinical settings as well as in a drug-discovery context, the impact of an agent that may affect reverse transcriptase (RT) can be measured and even quantified by bringing a sample, which may contain an RT, into contact with an RNA template, a primer complementary to the RNA template, and appropriate oligonucleotide-specific primers, under conditions such that they react, in the presence of RT, to form a cDNA product in inverse proportion to the effect of the agent. The amount of any resultant cDNA product then can be measured. The approach is readily implemented as a real-time, quantitative kinetic assay for RT activity.
Abstract:
The dissolution rate of a therapeutically active compound in an aqueous liquid is increased by: i) preparing an essentially dry mixture consisting essentially of a) a therapeutically active compound and b) a cellulose ether, ii) compacting the resulting mixture under pressure and iii) comminuting the compacted mixture.
Abstract:
The invention described herein provides methods of producing rAAV particles by culturing producer cells under conditions, such as temperature and pH, that promote release of virus.
Abstract:
This invention provides methods and compositions for producing high titer, substantially purified preparations of recombinant adeno-associated virus (AAV) that can be used as vectors for gene delivery. At the onset of vector production, AAV producer cells of this invention typically comprise one or more AAV packaging genes, an AAV vector comprising a heterelogous (i.e. non-AAV) transgene of interest, and a helper virus such as an adenovirus. The AAV vector preparations produced are generally replication incompetent but are capable of mediating delivery of a transgene of interest (such as a therapeutic gene) to any of a wide variety of tissues and cells. The AAV vector preparations produced according to this invention are also substantially free of helper virus as well as helper viral and cellular proteins and other contaminants. Also provided is a quantitative, high-throughput assay useful in the assessment of viral infectivity and replication, as well as in the screening of agents that affect viral infectivity and/or replication.
Abstract:
A granulate for use in a pharmaceutical composition and a pharmaceutical composition manufacture using the granulate, where the granule comprises an active pharmaceutical ingredient (API) having a poor water solubility (i.e., less than about 1 mg/mL) which is intimately associated with at least one pharmaceutically acceptable hydrophilic polymer. The granule optionally contains one or more pharmaceutically acceptable excipients, such as disintegrants, wetting agents, diluents, binders, lubricants, glidants, coloring agents and flavoring agents. The invention also relates to a process for preparing the pharmaceutical granulate and pharmaceutical compositions containing the granulate.